Summit Therapeutics Inc.

SMMT | NASDAQ

Price Alert Chart Builder DCF Calculator

$15.10

-$0.93 (-5.80%)

Nov 2, 2026, 11:41 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-5.80%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

28.1

+5.5 pts

Fundamentals Weak

Market Sentiment Bullish

Moat None

Sector Rank #837/1028 (Top 81%)

Full Analysis

Key Statistics

Market Data

Market Cap $12.05B

1D Range

14.74 16.02

52W Range

12.43 26.38

Valuation (TTM)

PE -14.31

PB 20.30

EV/EBITDA -14.16

Valuation (NTM)

Forward PE N/A

Forward PEG -3.44

Price Target $29.33

Cash Flow

FCF Yield -3.2%

SBC Adj. FCF Yield -5.7%

SBC Impact -79.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -94.3%

Dil EPS 3Y | 5Y -67.4% | -3.5%

FCF 3Y | 5Y -76.7% | -56.0%

Returns

ROA -113.8%

ROE -204.3%

ROIC -134.1%

Financial Health

Net Cash

$670.29M

Current Ratio 6.96

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States a...

Sector Healthcare

Industry Biotechnology

Employees 265

IPO Date Mar 5, 2015

Website www.smmttx.com

Fiscal Year January - December

Full Company Profile

Latest News

8 days ago · gurufocus.com

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n

8 days ago · businesswire.com

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today's Presidential Symposium II at the European Society for Medic.

10 days ago · gurufocus.com

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPR News

10 days ago · businesswire.com

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur.

11 days ago · zacks.com

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.

11 days ago · businesswire.com

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain. Across 10 presentations at ESMO 2026, ivonescimab data will span a broad range of tumor types, led by positive overall survival findings from Akeso Inc.'s Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy compared to du.

12 days ago · zacks.com

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.

12 days ago · prnewswire.com

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC.

12 days ago · businesswire.com

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl.